Differential diagnosis of obstetric thrombotic microangiopathy: a review

Cover Page

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Thrombotic microangiopathy (TMA) is a clinical and morphological syndrome, which is based on damage of the endothelium. Clinically, TMA is characterized by a triad of symptoms: thrombocytopenia, microangiopathic hemolytic anemia, and target organ damage. In obstetric practice, TMA most often occurs with preeclampsia or HELLP syndrome, atypical HUS, TTP. The review presents the basic differential criteria for the diagnosis of TMA during pregnancy and after childbirth, as well as the management of patients.

Full Text

Restricted Access

About the authors

Polina I. Kukina

I.M. Sechenov First Moscow State Medical University

Email: renoru47@gmail.com


Russian Federation, Moscow

Anastasiya V. Moskatlinova

I.M. Sechenov First Moscow State Medical University

Email: moskatav@mail.ru


Russian Federation, Moscow

Irina M. Bogomazova

I.M. Sechenov First Moscow State Medical University

Email: irinka.bogomazova@mail.ru
ORCID iD: 0000-0003-1156-7726

Assistant Professor

Russian Federation, Moscow

Elena V. Timokhina

I.M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: elena.timokhina@mail.ru
ORCID iD: 0000-0001-6628-0023

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow


  1. Kentouche K, Voigt A, Schleussner E, et al. Pregnancy in Upshaw-Schulman syndrome. Hamostaseologie. 2013;33(2):144–148. doi: 10.5482/HAMO-13-04-0025
  2. Akin’shina SV, Bitsadze VO, Andreeva MD, Makatsariya AD. Thrombotic microangiopathy. Prakticheskaya meditsina. 2013;7(76):7–19. (In Russ).
  3. Dashe JS, Ramin SM, Cunningham FG. The long-term consequences of thrombotic microangiopathy (thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) in pregnancy. Obstet Gynecol. 1998;91(5 Pt1):662–668.
  4. Grebennik TK, Ryabinkina IN, Pavlovich SV, et al. Statistics of pre-eclampsia and eclampsia. Materialy VIII Regional’nogo nauchnogo foruma «Mat’ i ditya»; 2015 June 29 – July 1; Sochi:163–164. (In Russ).
  5. Sarno L, Stefanovic V, Maruotti GM, et al. Thrombotic microangiopathies during pregnancy: The obstetrical and neonatal perspective. Eur J Obstet Gynecol Reprod Biol. 2019;237:7–12. doi: 10.1016/j.ejogrb.2019.03.018
  6. Kappler S, Ronan-Bentle S, Graham A. Thrombotic microangiopathies (TTP, HUS, HELLP). Emerg Med Clin North Am. 2014;32(3):649–671. doi: 10.1016/j.emc.2014.04.008
  7. Scully M. Thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome microangiopathy in pregnancy. Semin Thromb Hemost. 2016;42(7):774–779. doi: 10.1055/s-0036-1587683
  8. Fujisawa M, Yasumoto A, Kato H, et al. The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function. Br J Haemаtol. 2020;189(1):182–186. doi: 10.1111/bjh.16297
  9. Roose E, Joly BS. Current and future perspectives on ADAMTS13 and thrombotic thrombocytopenic purpura. Hamostaseologie. 2020;40(03):322–336. doi: 10.1055/a-1171-0473
  10. Makatsariya AD, Bitsadze VO, Khizroeva DKh. HELLP syndrome. Akusherstvo. Ginekologiya. Reproduktsiya. 2014;8(2):61–68. (In Russ).
  11. Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98:2730–2735. doi: 10.1182/blood.v98.9.2730
  12. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura: report of 25 cases and review of the literature. Medicine (Baltimore). 1981;60(6):413–428.
  13. Makatsariya AD, Bitsadze VO, Akin’shina SV, Andreeva MD. Pathogenesis and prevention of pregnancy complications caused by thrombotic microangiopathy. Voprosy ginekologii, akusherstva i perinatologii. 2013;12(6):63–73. (In Russ).
  14. Fakhouri F. Pregnancy-related thrombotic microangiopathies: Clues from complement biology. Transfus Apher Sci. 2016;54:199–202.
  15. Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5):859–867.
  16. Huerta A, Arjona E, Portoles J, et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2017;450–459. doi: 10.1016/j.kint.2017.06.022
  17. Gaggl M, Aigner C, Csuka D, et al. Maternal and fetal outcomes of pregnancies in women with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2018;29(3):1020–1029. doi: 10.1681/ASN.2016090995
  18. Haram K, Mortensen JH, Mastrolia SA, Erez O. Disseminated intravascular coagulation in the HELLP syndrome: how much do we really know? J Maternal Fetal Neonatal Med. 2017;30:779–788. doi: 10.1080/14767058.2016.1189897
  19. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600.
  20. Wu N, Liu J, Yang S, et al. Diagnostic and prognostic values of ADAMTS-13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura. Transfusion. 2015;15(1):18–24. doi: 10.1111/trf.12762
  21. Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643–657. doi: 10.1038/nrneph.2012.214
  22. Sibai BM. Imitators of severe preeclampsia. Obstet Gynecol. 2007;109:956–966.
  23. Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012;27(7):2673–2685. doi: 10.1093/ndt/gfs279
  24. Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic–uremic syndrome. N Engl J Med. 1995;333(6):364–368.
  25. Fujimura Y, Matsumoto M, Kokame K, et al. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol. 2009;144(5):742–754.
  26. Moatti-Cohen M, Garrec C, Wolf M, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119(24):5888–5897. doi: 10.1182/blood-2012-02-408914
  27. Hofer J, Giner T, Safouh H. Diagnosis and treatment of the hemolytic uremic syndrome disease spectrum in developing regions. Semin Thromb Hemost. 2014;40:478–486. doi: 10.1055/s-0034-1376154
  28. Wong EK, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res. 2015;165:306–320. doi: 10.1016/j.trsl.2014.10.010
  29. Abildgaard U, Heimdal K. Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. Eur J Obstet Gynecol Reprod Biol. 2013;166:117–123. doi: 10.1016/j.ejogrb.2012.09.026
  30. Mao M, Chen C. Corticosteroid therapy for management of hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome: a meta-analysis. Med Sci Monit. 2015;21:3777–3783.
  31. LeFevre ML; U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(11):819–826. doi: 10.7326/M14-1884.



Abstract: 109

Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2021 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies